Potent Raf-1 inhibitor; also inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and cKIT
Sorafenib is a potent Raf inhibitor (IC50 values are 6, 22 and 38 nM for Raf-1, wild-type BRAF and V599E BRAF mutant, respectively). Also inhibits mVEGFR-2, mVEGFR-3, mPDGFR-β, Flt-3, cKIT and VEGFR-2 (IC50 values are 15, 20, 57, 58, 68 and 90 nM, respectively). Inhibits MAPK pathway in colon, pancreatic and breast cancer cells expressing mutant KRAS and mutant or wt BRAF
in vitro
. Exhibits antitumor activity in colon, breast and non small-cell lung cancer xenograft models. Also induces ferroptosis in hepatocellular carcinoma cells
in vitro
| Marque | Tocris Bioscience |
|---|---|
| Réf. B-LABO | BL-RE-151133 |
| Réf. fabricant | 18766326 |
| Nom chimique ou matériau | 4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide |
| CAS | 284461-73-0 |
| Quantité | 50 mg |
| Formule moléculaire | C<sub>21</sub>H<sub>16</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>3</sub> |
| Poids de la formule | 464.82 |
| Pureté | 98% |
